Ghost Tree Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Ghost Tree Capital’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,367	Closed	-$968K	–	59
2019 Q4	$968K	Buy	+3,367	New	+$730K	0.18%	49
2018 Q2	–	Sell	-5,119	Closed	-$1.03M	–	53
2018 Q1	$1.03M	Buy	+5,119	New	+$1.02M	0.21%	49

Other funds holding KPTI

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Ghost Tree Capital's KPTI Position: Q1 2020 in Review

Ghost Tree Capital sold out of Karyopharm Therapeutics (KPTI) in Q1 2020, closing a stake of 3,367 shares — an estimated $968K sold.

Ghost Tree Capital first reported a position in KPTI in Q1 2018 and held it in 2 quarters. The position peaked at $1.03M in Q1 2018. 136 funds tracked by Wall St. Rank hold KPTI as of Q1 2020.

Ghost Tree Capital reported no remaining Karyopharm Therapeutics position as of Q1 2020 after selling out during the quarter.
Ghost Tree Capital sold 3,367 Karyopharm Therapeutics shares in Q1 2020, an estimated $968K.
Ghost Tree Capital first reported a position in Karyopharm Therapeutics in Q1 2018 and held it in 2 quarters.
Ghost Tree Capital's Karyopharm Therapeutics position peaked at $1.03M in Q1 2018.
136 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2020.

Based on Ghost Tree Capital's 13F filing for Q1 2020, filed 15 May 2020.